The Food and Drug Administration (FDA) has approved Evenity (romosozumab-aqqg; Amgen) injection for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a ...

Amgen recently had two big wins. First, after years of wrangling with the FDA, they finally won approval for their innovative osteoporosis drug, Evenity. Second, Amgen launched Evenity at a price ...

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab) to ...

The U.S. Food and Drug Administration has approved a drug treatment specifically for postmenopausal women with a high risk of breaking bones. Doses are taken in two back-to-back injections ...

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo. REUTERS/Robert Galbraith/Files By Deena Beasley (Reuters) - Amgen Inc ...

I read with great interest an article on the Osteoboost belt, which is the first medical device approved by the Food and Drug ...

DEAR DR. ROACH: I’ve been taking calcium supplements for many years to assist in strengthening my bones. I’m 74, weigh less than 95 pounds and stand 5 feet tall. I’m on the verge of osteoporosis, and ...

The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history ...

(Reuters) - Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections. The U.S. Food and Drug ...